GlassScriptPhysician profile
Scott Allen Farhart
NPI 1467470021
$4,415.60
in general payments reported to CMS, 2019-2025
38 companies · $667 in 2025
The $667 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $225 · 2021: $417 · 2022: $565 · 2023: $1,334 · 2024: $721 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,722.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $691.09 | 2019-2025 | |
| Exeltis, USA INC. | $512.14 | 2019-2025 | Slynd |
| Hologic Sales and Service, LLC | $380.91 | 2021-2025 | Aptima |
| Pfizer INC. | $342.59 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $328.71 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $301.84 | 2019-2024 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $300.06 | 2022-2025 | |
| Daiichi Sankyo INC. | $155.69 | 2019-2024 | Injectafer |
| Coopersurgical, INC. | $144.74 | 2019-2025 | Paragard T 380a |
| Organon LLC | $119.24 | 2021-2024 | Nexplanon |
| Biogen, INC. | $106.27 | 2024-2025 | Zurzuvae |
| Agile Therapeutics, INC. | $91.25 | 2021-2022 | |
| Myriad Women'S Health, INC. | $79.33 | 2023 | Myrisk |
| Avion Pharmaceuticals | $70.69 | 2020-2023 | Balcoltra |
| Vertex Pharmaceuticals Incorporated | $64.10 | 2024-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $58.16 | 2019-2021 | |
| Evofem Biosciences, INC. | $57.57 | 2021-2024 | Phexxi |
| Millicent US INC | $55.64 | 2019-2025 | Femlyv, Intrarosa |
| Abiomed | $53.81 | 2019 | |
| Meditrina | $50.27 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $48.67 | 2022-2024 | Gardasil, Gardasil 9 |
| Davol INC. | $39.41 | 2023-2025 | Arista Ah Flexitip, Arista |
| Myovant Sciences INC. | $33.53 | 2022 | |
| Shield Therapeutics INC | $32.71 | 2023 | Accrufer |
| Becton, Dickinson and Company | $31.94 | 2025 | Arista |
| Medtronic, INC. | $30.59 | 2022-2023 | V-Loc 180 |
| Duchesnay USA Incorporated | $29.75 | 2019 | |
| Amgen INC. | $29.09 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $25.94 | 2019 | |
| Sanofi Pasteur INC. | $24.49 | 2022 | |
| Novo Nordisk INC | $18.74 | 2023 | Wegovy |
| Dexcom, INC. | $17.68 | 2021 | |
| Mylan Pharmaceuticals INC. | $17.28 | 2021 | |
| Convatec INC. | $16.77 | 2023 | |
| Bard Access Systems, INC. | $15.39 | 2019 | |
| Boston Scientific Corporation | $13.37 | 2024 | |
| Lsi Solutions INC | $13.29 | 2024 | Fornisee |
| Therapeuticsmd, INC. | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Farhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.